{"id":"NCT02671500","sponsor":"Gilead Sciences","briefTitle":"Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV","officialTitle":"A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic HCV","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04-19","primaryCompletion":"2018-01-05","completion":"2018-03-27","firstPosted":"2016-02-02","resultsPosted":"2019-01-08","lastUpdate":"2019-01-08"},"enrollment":375,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus Infection"],"interventions":[{"type":"DRUG","name":"SOF/VEL","otherNames":["GS-7977/GS-5816","EpclusaÂ®"]}],"arms":[{"label":"SOF/VEL","type":"EXPERIMENTAL"}],"summary":"The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir (SOF)/velpatasvir (VEL; GS-5816) fixed-dose combination (FDC) for 12 weeks in participants with chronic hepatitis C virus (HCV) infection.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","timeFrame":"Posttreatment Week 12","effectByArm":[{"arm":"SOF/VEL (Overall)","deltaMin":96.5,"sd":null},{"arm":"SOF/VEL (China - Region 1)","deltaMin":96.2,"sd":null},{"arm":"SOF/VEL (Southeast Asia - Region 2)","deltaMin":97.3,"sd":null}],"pValues":[{"comp":"OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":4},"locations":{"siteCount":38,"countries":["China","Malaysia","Singapore","Thailand","Vietnam"]},"refs":{"pmids":["30555048"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":375},"commonTop":["Upper respiratory tract infection"]}}